Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.

Neurobiology of aging - 1 Aug 2011

Kester Maartje I, Verwey Nicolaas A, van Elk Evert J, Blankenstein Marinus A, Scheltens Philip, van der Flier Wiesje M

Abstract excerpt

OBJECTIVE: To study CSF biomarkers amyloid-beta 1-42 (Aβ42) and total tau (tau) in relation to APOE genotype in their ability to predict progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). METHODS: In 100 MCI patients CSF Aβ42, tau and APOE genotype were determined. At follow-up of 18 (13-24) months 58 patients remained non-progressive and 42 progressed to AD. RESULTS: Cox proportional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Apolipoprotein E4

Share to Cognitive Dysfunction

Share to Genetic Carrier Screening

Share to Peptide Fragments

Share to Predictive Value of Tests

Share to Severity of Illness Index

Source

Identifiers

PMID: 19748159
DOI: 10.1016/j.neurobiolaging.2009.08.006

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.PMID 19748159Read ↗

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.Semantic proximity Read ↗

Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.Semantic proximity Read ↗

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.Semantic proximity Read ↗

Assessment of apolipoprotein E genotype for β-amyloid status prediction.Semantic proximity Read ↗

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrationsSemantic proximity Read ↗

Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.Semantic proximity Read ↗

The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease.Semantic proximity Read ↗

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.Semantic proximity Read ↗

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)Semantic proximity Read ↗

Effects of APOE ε4 and amyloid pathology on longitudinal tau biomarkers, neurodegeneration, and cognitive decline in mild cognitive impairment.Semantic proximity Read ↗

An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.Semantic proximity Read ↗

Differential Associations of APOEɛ2 and APOEɛ4 Genotypes with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Individuals Without Dementia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.